Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2022-04-04
- Target Recruit Count
- 135
- Registration Number
- NCT03832621
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 95
- Registration Number
- NCT03818685
- Locations
- 🇫🇷
Hopital Prive Jean Mermoz, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Clinique de la Sauvegarde, Lyon, France
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
- Conditions
- Pathologic Stage IV Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Metastatic Basal Cell CarcinomaMetastatic Merkel Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaPathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Unresectable Merkel Cell CarcinomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03816332
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT03815890
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Netherlands
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients with HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Basaloid CarcinomaPathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Posterior Tongue Squamous Cell CarcinomaSoft Palate Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell Carcinoma AJCC V7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT03799445
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- Conditions
- Clear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph NodesMetastatic Malignant Neoplasm in the Soft TissuesMetastatic Malignant Neoplasm in the VisceraRhabdoid Tumor of the KidneySarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1175
- Registration Number
- NCT03793166
- Locations
- 🇺🇸
Northside Hospital - Gwinnett, Lawrenceville, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
🇺🇸Hawaii Cancer Care - Westridge, 'Aiea, Hawaii, United States
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03789110
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 40
- Registration Number
- NCT03784040
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer
- Conditions
- Clinical Stage 0 Gastric Cancer AJCC V8Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastric Cancer AJCC V8Clinical Stage I Gastric Cancer AJCC V8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IVA Gastric Cancer AJCC V8Gastric AdenocarcinomaClinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03776487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Columbia University
- Registration Number
- NCT03767439
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.